In the last three months, we have seen rapid regulatory approvals for Emgality (galcanezumab) in the US and EU, and for Ajovy (fremanezumab) in the US.

Catch up at:

Emgality (galcanezumab) receives EU approval in migraine prevention »

Emgality (galcanezumab) approved for migraine prevention in USA »

Ajovy (fremanezumab) wins US approval in migraine prevention »

With three anti-CGRP therapies now available to clinicians, Editor-in-Chief, Dr David Dodick, has written a very timely ‘Hot Topic’ on where these novel agents fit within the therapeutic options for migraine.

Catch up at:

Anti-CGRP therapy: where does it fit in our clinics? »

From two major conferences this Autumn, we reported latest results from CGRP inhibitor trials, including the PROMISE-1 study of eptinezumab, and novel insights from erenumab responder data.

Catch up at:

Eptinezumab acts fast and has sustained activity in episodic migraine »

Erenumab responder data may help set expectations for migraine frequency and disability with ongoing prophylaxis »

Further reports from the Autumn conferences focus on additional recent advances in understanding and treatment of migraine.

Catch up at:

12th European Headache Federation Congress »

17th Biennial Migraine Trust International Symposium »

For all the other recent migraine news featured on the CGRP Forum click here »